Consensus Edwards Lifesciences Corporation
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.35 USD | -0.17% |
|
-0.27% | -1.06% |
Evolution of the Average Target: Edwards Lifesciences Corporation
Evolution of the Target Price: Edwards Lifesciences Corporation
Changes in Analyst Recommendations: Edwards Lifesciences Corporation
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +14.44% | |||||
| +4.3% | |||||
| +12.36% | |||||
| +8.82% | |||||
| +42.07% | |||||
| +19.68% | |||||
| +16.73% | |||||
| +11.93% | |||||
| +11.5% | |||||
| +36.28% | |||||
| Average | +17.81% | |||||
| Weighted average by Cap. | +15.39% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| UBS | |
| Barclays | |
| Baird | |
| Goldman Sachs | |
| TD Cowen | |
| Evercore ISI | |
| JPMorgan Chase | |
| Canaccord Genuity | |
| Citigroup | |
| Leerink Partners | |
| Bernstein | |
| Raymond James | |
| Truist Securities | |
| RBC Capital Markets | |
| Stifel Nicolaus | |
| BTIG | |
| Wells Fargo Securities | |
| Argus | |
| Daiwa Securities | |
| Piper Sandler | |
| Rothschild & Co Redburn | |
| Deutsche Bank Securities | |
| Mizuho Securities | |
| Jefferies & Co. | |
| Wolfe Research | |
| Oppenheimer | |
| DBS Bank | |
| CICC Research | |
| Morgan Stanley | |
| BofA Securities | |
| Redburn Atlantic | |
| Nephron Research | |
| Zacks Investment Research | |
| Cowen | |
| SVB Leerink | |
| Credit Suisse | |
| Atlantic Equities |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EW Stock
- Consensus Edwards Lifesciences Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition